Commercial Incentives

How it works

Risks & contraindications

Highlighted claims

• Push incentives reduce the cost and risk of drug research and development. — Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries
• Pull incentives create demand-side commercial rewards such as advance market commitments and subsidies. — Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries
• Pulley mechanisms are proposed as research models that amplify existing research outputs for large impact from modest investment. — Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries
• Cost-based pricing weakens incentives to fund studies that improve dosing guidance for existing medicines. — Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries
• Weak intellectual property and market-exclusivity protections can make paediatric medicine development in LMICs commercially unattractive. — Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries
• Limited market size, low ability to pay, and cost-based pricing further reduce incentives for paediatric drug research in LMICs. — Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries